HIGHLIGHTS
- What: The authors investigated the efficacy of fingolimod and natalizumab in POMS in a multicentre setting. The authors observed that clinicians usually prescribe natalizumab more frequently than fingolimod in POMS patients showing higher inflammatory activity.
- Who: Antonio Carotenuto from the This is a multicentre longitudinal retrospective studyWe included POMS patients from , Italian MS Centres (1.Federico II University, Naples have published the research work: Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod, in the Journal: (JOURNAL)
- How: The authors collected Annual Relapse Rate (ARR) Expanded Disability Status Scale . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.